Search
ATG-101
go.drugbank.com/drugs/DB17162Investigational, while delivering enhanced anti-tumor activity, with an improved safety profile. … ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors
Synonyms: PD-L1/4-1BB bispecific antibodyTopsalysin
go.drugbank.com/drugs/DB05160InvestigationalTopsalysin is being developed for the treatment of localized prostate cancer and also benign prostatic hyperplasia. Topsalysin is delivered locally to the prostate under ultrasound guidance.
Cholesteryl chloride
go.drugbank.com/drugs/DB14045ExperimentalCholesteryl chloride, also known as 3-chlorocholest-5-ene, is an organochloride derivative of cholesterol. It is presented as a liquid crystal that forms clockwise liquid crystals.
Synonyms: 3-Chlorocholest-5-eneBenzbromarone
go.drugbank.com/drugs/DB12319ApprovedWithdrawnBenzbromarone has been used in trials studying the basic science and treatment of Heart Failure, Hyperuricemia, Chronic Kidney Disease, Abnormal Renal Function, and Gout and Asymptomatic Hyperuricemia.
TZP-102
go.drugbank.com/drugs/DB16129InvestigationalTZP-102 is under investigation in clinical trial NCT01452815 (Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis).
LuLym-T
go.drugbank.com/drugs/DB17405ExperimentalLuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.
Phentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationalPhentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation.
Synonyms: 2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazolinePorphobilinogen
go.drugbank.com/drugs/DB02272ExperimentalPorphobilinogen is a pyrrole involved in porphyrin metabolism. It is generated by the enzyme ALA dehydratase, and converted into hydroxymethyl bilane by the enzyme porphobilinogen deaminase.
Reglitazar
go.drugbank.com/drugs/DB04971ExperimentalReglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.
ADX-10061
go.drugbank.com/drugs/DB05419ExperimentalADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.